PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics.  Under current news, you will find a dynamic list of stories for the last thirty (30) days.  You will find older news stories in our archives.    Stories about specific treatments can also be found in the medical section.

If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added.   Send news:  contact/info+phcentral+org.

  • November 22, 2014
  • An IPF Game-Changer: A Primer on the Newly Approved Drugs
  • (Medscape) In October, the US Food and Drug Administration (FDA) approved two new drugs, nintedanib (Ofev®, Boehringer Ingelheim) and pirfenidone (Esbriet®, InterMune), to help manage this condition. Medscape Advisory Board member for Pulmonary Medicine, Steven Nathan, MD, was a principal investigator in studies on pirfenidone and nintedanib.

    Dr Nathan recently spoke to Medscape about the importance of the new drug approvals, how the drugs work, and how physicians might use them to potentially extend the lives of their patients.
  • UC San Diego Health System Launches First US CTEPH Registry
  • (Pulmnonary Hypertension News) The University of California San Diego Health System, a leader in chronic thromboembolic pulmonary hypertension (CTEPH) research and patient care, has just received a generous grant to fund the recent launch of the country’s first CTEPH registry. The $7.6 million grant comes from pharmaceutical giant Bayer HealthCare in time for the November Pulmonary Hypertension Awareness Month. UC San Diego Health System is also known for being the first to offer pulmonary thromboendarterectomy (PTE), a life-saving, curative procedure for CTEPH, which is currently available in less than 10 facilities nationwide.
  • November 21, 2014
  • Pulmonary Arterial Hypertension: A Better Understanding of the Three New Drug Therapies
  • (MedScape) Interview with Dr Nathan where the three new meds. are explained and compared.

    Medscape: I understand that three new drugs to treat PAH have been approved in the past year or two.
    Dr Nathan: Yes, indeed. The three drugs are riociguat (Adempas®), which acts on the nitric oxide pathway and further downstream as a direct guanylate cyclase stimulator, as well as sensitizing the receptor to endogenous nitric oxide. The second is an endothelin receptor antagonist (ERA) called macitentan (Opsumit®). The third is oral treprostinil, marketed as Orenitram™, which is the same compound as the treprostinil that is now used for intravenous, subcutaneous, or inhaled administration.....
    Medscape: Where do you think the menu of treatments for PAH is going?
    Dr Nathan: Thankfully, despite the availability of many treatment options, there's growing interest in developing new drugs. There are a number of agents in development beyond the currently available drugs, which mainly address the balance between vasodilation and vasoconstriction. These investigational therapies include antiproliferative agents, aimed at the root cause of PAH, with the potential of being more potent disease modifiers.
  • Patients With Reactive Pulmonary Hypertension Present Higher Mortality Risk
  • (Pulmonary Hypertension News) Pulmonary hypertension (PH) is uniformly defined as high pressure in the pulmonary vasculature but can be divided into three groups: active, passive, and reactive. According to the Department of Anaesthesia & Intensive Care of Chinese University of Hong Kong, passive PH is due to high pressure in post-pulmonary capillaries, active PH is due to obstructions in capillary and precapillary vessels, and reactive PH is due somewhat to an active-superimposed-on-passive component.
  • Marathoner Tells How She Deals with Exercise-Induced PH, Advocates for Early Diagnosis
  • (Lung Disease News) Roseanne Huber was like any other 40-year-old woman that had decided to improve her quality of life getting in shape, when, after experiencing symptoms of shortness of breath and a misdiagnosis, the doctors told her she suffered from exercise-induced pulmonary hypertension (PH), an untreatable disease. Eight years later, she explained to the Pulmonary Hypertension Association (PHA) on their blog how they helped her manage the rare and debilitating disease, while not having to abandon her passion for exercise.
  • New Stem Cell Treatment for IPF
  • (Lung Disease News) Generation of iPSC Suggests New Idiopathic Pulmonary Fibrosis Stem Cell Treatment
    ...a team of researchers, Amiq Gazdhar and colleagues, sought to evaluate the potential of induced pluripotent stem cells (iPSC) conditioned media (iPSC-cm) to regenerate and repair the alveolar epithelium in vitro and improve bleomycin induced lung injury in vivo....
    The most common cause of death related to IPF is respiratory failure. Other causes of death include pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, and lung cancer....recently, cell based approaches have been proposed as new possibilities to regenerate various organs, including the fibrotic lung.

    The generation of human induced pluripotent stem cells (iPSC) has opened up a new avenue for patient-specific cell based therapies.
    In this study, researchers showed that conditioned media obtained from iPSC improved alveolar epithelial repair in vitro and attenuated bleomycin induced lung injury and fibrosis in vivo
  • November 20, 2014
  • AHA’s Scholarly Journal Plans New Thematic Series Covering Advances in PH
  • (PulmonaryHypertensionNews) The American Heart Association’s (AHA) journal Circulation has announced plans for a new thematic series on the recent advances in diagnosing and treating Pulmonary Hypertension (PH),
  • November 19, 2014
  • PH Therapy Riociguat To Be Tested as Diffuse Cutaneous Systemic Sclerosis Drug
  • (Lung Disease News) Bayer HealthCare recently announced the launch of a new clinical trial, the RISE-SSc study, a randomized, double-blind, placebo-controlled Phase II study to investigate the efficacy and safety of riociguat against placebo in patients with diffuse cutaneous systemic sclerosis (dcSSc), the most severe form of systemic sclerosis (SSc). Both Bayer and Merck & Co., Inc., known as MSD outside of the U.S. and Canada, established a strategic collaboration in the field of modulation of soluble guanylate cyclase (sGC) for the development of riociguat in cutaneous systemic sclerosis.
  • PH Patients Meet with Congress
  • (PulmonaryHypertensionNews) PH patients from across the country yesterday to meet with Members of Congress.... to boost support for national efforts against this life threatening cardiopulmonary disease, they discussed the everyday plight of PH patients in the country, and encouraged cosponsorship of the Pulmonary Hypertension Research and Diagnosis Act (H.R. 2073, S. 1453).
  • November 18, 2014
  • Screening for Connective Tissue Disease in Pulmonary Arterial Hypertension
  • (MedScape) Objectives To evaluate the utility of anti-nuclear antibody (ANA) levels in distinguishing the cause of pulmonary arterial hypertension as idiopathic (IPAH) or connective tissue disease related (CTD-PAH).
  • November 17, 2014
  • Delhi doctors cure Zimbabwean woman of rare artery disorder
  • (Daily Mail) Thirty-six-year-old Margaret was initially diagnosed with primary pulmonary hypertension, a disorder where patients have high blood pressure in the arteries in their lungs.

    Doctors in Zimbabwe began medication and expected a speedy recovery. However, despite going through extensive treatment, she had no relief...That’s when the doctors decided to start from scratch. They found out that Margaret's pulmonary artery pressure was 120 mmHG, when it should have been between 18 and 30 mmHG.

    Medical tests later confirmed that she was actually suffering from a rare condition called isolated pulmonary artery stenosis.

    “We carried out a CT scan of the lungs and angiography of the right side of her heart. We found out that branches of arteries going to the lungs were completely blocked. This blockage was not detectable in a cardiac echo,” said Dr Naveen Bhamri, associate director in cardiology department at Max Hospital, Shalimar Bagh.
    Two days after the surgery, Margaret was discharged. The overall treatment cost her about Rs 1.5 lakh.

    “Now, I am even fit to participate in a marathon. After being bothered by this disorder for 20 years, it is hard to believe that I have been relieved from the ailment,” a cheerful Margaret said
  • November 16, 2014
  • Newly Identified Blood Signatures Help Map Successful PAH Treatments
  • (Pulmonary Hypertension News) In a perfect world, equivalent responses to treatments from patients with pulmonary hypertension would make all treatment outcomes predictable and highly effective. In reality, this is not the case. However, distinguishing subtypes of pulmonary arterial hypertension can at least improve treatment outcomes by better matching patients to treatments using genetic signatures interpreted from blood samples.
  • New Insights For Cardiac Assessment Before Administering Stem Cell Therapy in Scleroderma
  • (Scleroderma News) The ASTIS trial (Autologous Stem cell Transplantation International Scleroderma), launched in 2001, evaluated the efficacy of autologous haematopoietic stem cell transplantation (HSCT) in patients with systemic sclerosis. A key point to safe use of HSCT is a correct evaluation of cardiac condition, and a close follow up for cardiac complications. In a letter to the Editor published in The Journal of the American Medical Association, entitled “Cardiac Assessment Before Stem Cell Transplantation for Systemic Sclerosis,” Dr. Burt at the Division of Immunotherapy, Northwestern University and colleagues highlight the importance of performing extensive cardiopulmonary screening in patients with severe forms of systemic sclerosis before administrating HSCT.
  • November 15, 2014
  • Combination Therapy for PAH: AMBITION Study Yields Impressive Results
  • (Pulmonary Hypertension R.N.) Gilead recently presented the results of AMBITION, their largest PAH study. This study compared the long term outcomes of pulmonary arterial hypertension patients who had been recently diagnosed and were randomized to either Tadalafil (Adcirca), Ambrisentan (Letairis) or the combination of the two. For the past decade there has been heated debate as to whether patients should be started on a single therapy or multiple therapies at the same time. We can now unequivocally concluded that functional class 2 and 3 patients who are previously untreated with PAH medications should be started on Ambrisentan and Tadalafil within a few weeks of each other. This strategy led to a 50% reduction in clinical failure.   Furthermore, combination therapy resulted in much improved exercise capacity, and improvements in blood tests reflecting heart function. The benefits were the same regardless of whether patients were from North America or outside of North America. Side effects occurred in many patients but these were manageable.
  • Riociguat benefits subgroup of pulmonary hypertension patients
  • (Cardiology News) Patients with pulmonary hypertension due to systolic left ventricular dysfunction show marked hemodynamic and quality of life improvements in response to oral riociguat if they have low baseline pulmonary vascular resistance, but not if their baseline pulmonary vascular resistance exceeds 240 dyn s/cm5, Dr. Marc J. Semigran reported at the annual meeting of the Heart Failure Society of America.
  • November 14, 2014
  • HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension
  • (Science Direct) Statins may intensify the beneficial effects of imatinib in PAH, which may be due to the additional influence of statin on the decrease of platelet-derived growth factor (PDGF)-induced effects. These properties allow the dose of imatinib used in PAH treatment to be reduced and thereby might improve its safety profile...
  • November 13, 2014
  • American Heart Association Publishes Major Update on Pulmonary Hypertension Advances
  • (Pulmonary Hypertention News) In terms of epidemiology and prognosis, the AHA notes that PH prevalence remains unknown, with an estimation that 83% of patients with heart failure have PH. PH is considered to be a disease with multifactorial etiology. In terms of classification, PH diagnoses can fall into 5 distinct groups: PAH (Group 1); PH secondary to left heart disease (Group 2); PH secondary to lung disease (Group 3); chronic thromboembolic PH (Group 4); and PH secondary to unclear or multifactorial mechanisms (Group 5).
  • Australia leads in pulmonary hypertension survival
  • (Rheumatology Update) Australian doctors have slashed the amount of time it takes to diagnose a patient with pulmonary hypertension, says cardiologist Professor Anne Keogh. They have also boosted survival, which for patients with the pulmonary arterial form of the disease is the best in the world, she says. Five years ago the delay in diagnosis was three years and nine months. However, the Pulmonary Hypertension Society patient register shows this has been reduced to less than a year on average. The overall survival in Australia has risen from a median of six months in 1999 to seven years at present.
  •  The dangers from dust
  • (The Press) The irritation sets up an inflammatory response which results in fluid production which reduces the lungs' efficiency. This causes the characteristic wheezy out-of-breathness associated with asbestosis. 
  • Indian scientists find cure for pulmonary blood pressure
  • (Deccan Chronicle) Hyderabad: Indian researchers at the Max Planck Institute for Heart and Lung Research have made a crucial breakthrough in finding a treatment for pulmonary hypertension. A cure to the disease, which can lead to heart failure, was hitherto unknown.
  • November 12, 2014
  • Scientists Identify a Role for Carbon Monoxide in Battling Bacterial Infections
  • ( Newswise — BOSTON – The innate immune system serves as the body’s specialized armed forces division, comprised of a host of defense mechanisms used to battle bacterial infections. Among the system’s warriors are white blood cells including the specialized macrophages, which maintain constant surveillance for foreign intruders or pathogens, functioning as the body’s first line of defense, poised to attack at barrier sites including the skin, lungs and intestines.
    Now, a research team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) finds that naturally occurring carbon monoxide (CO) is essential for the macrophages’ carefully crafted surveillance plan and subsequent attack...
  • Safety Concerns Disqualify Scleroderma/PH Patients for Stem Cell Trial
  • (Pulmonary Hypertenson News) Patients with systemic sclerosis hoping to enroll in clinical trials investigating hematopoietic stem cell transplantation may be disqualified if they have pulmonary hypertension. During the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, reasons for turning away interested patients included pulmonary hypertension and left ventricular ejection fraction less than 45%.
  • November 11, 2014
  • Clinical Diagnosis of Pulmonary Hypertension
  • (Circulation) PAH remains a challenging disease. Because it is uncommon, it is difficult for physicians to develop sufficient experience and expertise unless they are part of a specialty PH Center. The cause can be multifactorial, making it difficult to know the dominant cause in some patients and thus requires a meticulous approach to arrive at the correct diagnosis. Also, the RV has traditionally been difficult to study because of its unique geometry and the lack of simple, reliable, and quantifiable noninvasive assessments. The emergence of CMR and other innovative modalities such as PET and measurements of ventriculoarterial coupling are encouraging..
    Detailed fulltext article
  • November 10, 2014
  • Magnetic resonance imaging may accurately measure pulmonary hypertension
  • (Radiology) MR-derived duration of vortical blood flow within the main pulmonary artery were associated with increased mean pulmonary arterial pressures. Duration of vortical blood flow on MR greater than 14.3% of cardiac interval was found to be specific for pulmonary hypertension.
  • Pulmonary Hypertension Diagnosis Aided By HD Medical's New Visual Murmur Stethoscope
  • (Pulmonary Hypertension News) “HD Medical’s ViScope MD is uniquely capable of determining the presence of a murmur during early screening,” said Muthu Krishnan, Senior Vice President of Business Development, HD Medical, Inc. ”This capability ensures patients can receive early intervention before irreversible pulmonary hypertension or heart failure intervenes.”
    Heart murmurs are characteristic signs of turbulent blood flow in cardiovascular structures. They can alert a physician to a stenosed artery, malfunctioning valve, and blood back flow, such as in PH, where the right side of the heart becomes congested because blood cannot adequately enter the lung vasculature.
  • November 9, 2014
  • Novel miRNAs and Molecule Inhibitors to Treat PAH
  • (Pulmonary Hypertension News) Naturally occurring microRNA molecules (miRNA) hold the potential to be a new treatment for pulmonary artery disease. A group at Sookmyung University and Yale University led by Professor Kim Jong-min investigated the causes of pulmonary arterial hypertension and discovered new molecular mechanism contributing to the disease.
  • Patient Inspires Kids With Rare Lung Disease
  • (Health News Digest) Sean Wyman was diagnosed with pulmonary arterial hypertension (PAH) on his 19thbirthday. PAH is a progressive, life-threatening disease in which high blood pressure in the arteries of the lungs (the pulmonary arteries) make it difficult for the heart to supply blood to the lungs. The disease affects approximately 200,000 patients worldwide.
  • November 8, 2014
  • Unlocking the secrets of pulmonary hypertension
  • (Medical XPress) A UAlberta team has discovered that a protein that plays a critical role in metabolism, the process by which the cell generates energy from foods, is important for the development of pulmonary hypertension, a deadly disease.
  • Lung Donation After Cardiac Death Shows Promise
  • (MedPage Today) Lung transplantation after cardiac death achieved key endpoints comparable to those attained with grafts obtained from brain-dead donors, according to a meta-analysis reported here.
  • November 7, 2014
  • Physical Exam Unreliable in Predicting Pulmonary Hypertension
  • (Pulmonary Hypertension News) While the majority of individuals suspected of having pulmonary hypertension would prefer to receive a physical examination to confirm diagnosis, invasive right heart catheterization may still offer the most reliable indication of diagnosis. “Utility of the Physical Examination in Detecting Pulmonary Hypertension: A Mixed Methods Study,” published in PLOS One by a team from the University of Toronto and Hamilton General Hospital in Canada, revealed that while a few metrics determined through physical examination may be associated with pulmonary hypertension, their use in detecting pulmonary hypertension in unreliable.
  • (Lung Disease News) In a study entitled “Sirtuin 3 Deficiency Is Associated with Inhibited Mitochondrial Function and Pulmonary Arterial Hypertension in Rodents and Humans” published in Cell Metabolism, researchers report a mitochondrial protein, Sirtuin 3, as the underlying link between inhibited mitochondrial function and pulmonary arterial hypertension.
  • November 6, 2014
  • Researchers Show How Microvasculature is Involved in CTEPH Pathogenesis
  • (Pulmonary Hypertension News) Patients with chronic thromboembolic pulmonary hypertension (CTEPH) who respond differently to treatment with pulmonary endarterectomy (PEA) may have differences in microvascular structure. When a team of researchers from Paris-South University and Centre Chirugical Marie Lannelongue investigated CTEPH pathogenesis in humans, they applied their findings related to microvasculature changes to generate an animal model of CTEPH that sufficiently reproduced the disease.
  • Pulmonary Hypertension Treatment Guidelines Updated At Recent ACCP Meeting
  • (Pulmonary Hypertension News) At the recent American College of Chest Physicians’ (ACCP) meeting, Darren Taichman, MD, PhD, executive deputy editor of the Annals of Internal Medicine, together with a colleague, presented updated information concerning diagnosis and treatment of pulmonary hypertension, based on what is known as evidence-based clinical practice guidelines.
  • Pulmonary Arterial Hypertension Reveals Characteristics Similar To Diabetes, Cancer
  • (Pulmonary Hypertension News) The narrowing of the blood arteries seen in PAH is caused by an uncontrollable growth of cells in the arteries’ walls, resembling the growth of cancer cells. Furthermore, these cells are insulin resistant, as seen in diabetes. Previous research conducted by Evangelos Mickelakis’ team had suggested that mitochondria are involved in the development of PAH, diabetes, and cancer.
  • November 5, 2014
  • Males With Scleroderma Found To Be More Affected By Pulmonary Hypertension
  • (Pulmonary Hypertension News) In a study entitled “A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study” published in the November issue of  Annals of the Rheumatic Diseases journal, the authors sought to understand the effects of gender on the systemic sclerosis phenotype and prognosis. ? Specifically, they found males to be independent predictors of Systemic sclerosis associated life-threatening conditions, such as Pulmonary Hypertension and Heart Dysfunction.
  • November 4, 2014
  • Better Quality of Life May Improve Pulmonary Hypertension Survival
  • (Lung Disease News) In addition to curing a disease, slowing disease progression, or repairing damage, one of the hallmarks of groundbreaking treatments for today’s most pressing health concerns is the degree to which a therapy can improve a patient’s health-related quality of life (HRQoL). Recently, a group of researchers from Sao Paulo, Brazil published a report on a study that sought to establish the efficacy of aiming for improvement of HRQoL in improving disease outcomes, particularly in pulmonary arterial hypertension (PAH). The report is available in Health and Quality of Life Outcomes journal.
  • November 3, 2014
  • £7.5 million boost for world-leading lung imaging research
  • (University of Sheffield News) The Academic Unit of Radiology in the University’s Department of Cardiovascular Science, one of key research groups contributing to the recently established Insigneo Institute for in silico Medicine, is internationally leading in the research and development of technology for clinical lung imaging with hyperpolarised gases and proton MRI which provide very detailed images of patient’s lungs without relying on X-rays radiation.
  • November 2, 2014
  • Utility of the Physical Examination in Detecting Pulmonary Hypertension. A Mixed Methods Study
  • (Plos One) Patients with pulmonary hypertension (PH) often present with a variety of physical findings reflecting a volume or pressure overloaded right ventricle (RV). However, there is no consensus regarding the diagnostic utility of the physical examination in PH.
  • Erectile-Dysfunction Drugs Also Give the Heart a Boost
  • (Medscape) For individuals with left ventricular hypertrophy (LVH), long-term use of an erectile-dysfunction drug can prevent cardiac remodeling, while use of these phosphodiesterase type-5 (PDE-5) inhibitors, which include the popular sildenafil (Viagra, Pfizer), can also improve measures of cardiac performance in subjects with a range of clinical diagnoses.
  • November 1, 2014
  • Keeping Pace With Evidence-Based Medicine: Pulmonary Hypertension Guideline Updates and Beyond
  • (AJMC) According to experts at the 2014 American College of Chest Physicians (ACCP) meeting, evidence-based guidelines are increasingly becoming “living” documents that are continuously updated. Darren Taichman, MD, PhD, executive deputy editor of the Annals of Internal Medicine and adjunct associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, presented updates to the ACCP guideline for diagnosis and treatment of pulmonary hypertension (PH) during a panel discussion.
  • ProMetic Submits Idiopathic Pulmonary Fibrosis Therapy PBI-4050 For Orphan Drug Status
  • (Pulmonary Hypertension News) ProMetic Life Sciences Inc. is currently preparing an Orphan Drug Designation (ODD) request for the company’s novel Idiopathic Pulmonary Fibrosis (IPF) drug PBI-4050 to the Food and Drug Administration (FDA).
  • October 31, 2014
  • Implant Eliminates External Pump in Pulmonary Hypertension
  • (MedScape) An implantable, programmable device safely delivers prostanoid treprostinil to patients with pulmonary arterial hypertension, according to new research presented here at CHEST 2014.
  • Liver Disease Can Cause Pulmonary Hypertension
  • (AmericanLiverFoundation) In the U.S. alone, it is estimated that over 30 million, or 1 out of every 10 Americans, have some form of liver disease, such as hepatitis, non-alcoholic fatty liver, or hepatic cancer. Liver diseases can lead to portopulmonary hypertension (POPH), a form of pulmonary arterial hypertension.
  • Researchers find novel way to treat pulmonary arterial disease
  • (The Korea Herald) A group of scientists from Korea and the United States have managed to find a new way to treat blockages in the artery that connects the heart and the lungs, officials said Wednesday.
  • October 30, 2014
  • New Overview Underscores Recent Progress in PAH Treatments
  • (Pulmonary Hypertension News) To date, twelve therapies have been approved to treat pulmonary arterial hypertension (PAH). Of these, three were approved last year, indicating significant progress in understanding and treating PAH. These advancements were greatly needed, as according to the recent publication of “Pulmonary Arterial Hypertension: Progress and Challenges in the Modern Treatment Era,” a new treatment overview published in AJMC for the chronic, progressive disease that affects two out of every one million individuals each year.
  • Scleroderma-Related PAH
  • (PubMed) This review summarizes recent advances in pulmonary hypertension, a leading cause of morbidity and mortality in scleroderma (SSc).
  • October 29, 2014
  • Lack of transcription factor FoxO1 triggers pulmonary hypertension
  • (Medical XPress) Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim and Giessen University have discovered that transcription factor FoxO1 regulates the division of cells and plays a key role in the development of pulmonary hypertension. The researchers were able to cure pulmonary hypertension in rats by activating FoxO1. The study findings could be used to develop a new treatment for this hitherto incurable disease.
  • New Pulmonary Arterial Hypertenion Research Highlights PAH-Related Myopathy, Importance of Exercise
  • (Nutrition, Metabolism and Cardiovascular Diseases) PAH research suggests that patients’ muscles are affected by the disease at the cellular level, and that any measure of exercise can have a palpably positive impact on health and well being.
    Skeletal muscles of PAH patients show a wide spectrum of cellular abnormalities that finally culminate in muscle atrophy and reduced contractility. Exercise training improves muscle function and bears a positive impact on clinical outcomes of PAH patients.
  •  ‘Dead heart’ transplant breakthrough at St Vincent’s Hospital
  • (The Australian) A SYDNEY surgeon has successfully transplanted “dead” hearts into three patients, in a breakthrough that could dramatically boost the survival prospects of people with serious heart disease.
  • October 28, 2014
  • Sildenafil-Treated PAH, Scleroderma Patient Shows Remarkable Improvements
  • (SpringerPlus) ....a 40 year old female with diffuse cutaneous systemic sclerosis, showed remarkable improvement in her pulmonary arterial hypertension following daily treatment with sildenafil.
    This case study adds to a previous report of a patient with small vessel vasculitis and Takayasu arteritis. In both studies, sildenafil was credited with enhancing vasodilation and inhibiting over proliferation of cells that can thicken vessel walls. These two successes led the authors to conclude that sildenafil ought to be further exploited for the treatment of patients with pulmonary arterial hypertension associated with scleroderma.
  • October 27, 2014
  • Caution Around Potting Mix
  • (Sunlive) Compost, potting mix and garden soils often contain the bacteria which cause legionellosis – also known as Legionnaires' disease.
  • Rho-kinase inhibitor decreased pulmonary vascular resistance and pressure, right ventricular hypertrophy and systolic dysfunction
  • (American Journal of Respiratory Cell and Molecular Biology) A new study entitled “Rho-kinase Mediates Right Ventricular Systolic Dysfunction in Rats with Chronic Neonatal Pulmonary Hypertension” published in the October issue of American Journal of Respiratory Cell and Molecular Biology reports that Rho-kinase activity is critical to systolic dysfunction in murine (rat) models of neonatal pulmonary hypertension.
    The inhaled Rho-kinase inhibitor normalized pulmonary vascular resistance and rescued right ventricular hypertrophy and pulmonary arterial wall remodeling.

  • October 26, 2014
  • HRQoL goals may improve outcome in PAH
  • (medwireNews) Health-related quality of life (HRQoL) before and during treatment for pulmonary arterial hypertension (PAH) is significantly associated with survival, Brazilian researchers report.
  • How 'vampire op' sucked all the blood from me to help me breathe again
  • (The Daily Mail) It sounds like a scene from a horror movie. As almost every drop of blood was drained from Annette Malocco’s body, for 20 minutes she ‘died’ on the operating table at Papworth Hospital.

    Yet surgeons were saving her life. Annette was undergoing a pulmonary endarterectomy, a pioneering operation which put her into a corpse-like state as a heart-lung machine took over the work of these vital organs and her blood was removed.
  • October 25, 2014
  • Echocardiographic Prediction of Pre- versus Postcapillary Pulmonary Hypertension
  • (Journal of the American Society of Echocardiography) The differential diagnosis between pre- and postcapillary pulmonary hypertension (PH) is of major therapeutic relevance and thus requires optimal clinical probability assessment with echocardiography.
  • An Update on Scleroderma-Related PAH
  • (Pulmonary Hypertension News) While it is commonly accepted that patients with scleroderma are at a higher risk for contracting pulmonary hypertension, the field has progressed immensely since the first hypothesis was tested in the laboratory. “Recent Advances in Scleroderma-associated Pulmonary Hypertension,” published in Current Opinion in Rheumatology by Dr. Kristin Highland at the Respiratory Institute in the Cleveland Clinic Foundation, concisely reviewed the wealth of knowledge gained over the years relating to scleroderma and pulmonary hypertension.
  • Vascular receptor autoantibodies implicated in SSc-PAH
  • (medwireNews) Autoantibodies to endothelin receptor type A (ETAR) and angiotensin receptor type-1 (AT1R) predict the development of, and mortality from, systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH), research suggests.
  • October 24, 2014
  •  ‘Dead heart’ transplant breakthrough at St Vincent’s Hospital
  • (The Australian) A SYDNEY surgeon has successfully transplanted “dead” hearts into three patients, in a breakthrough that could dramatically boost the survival prospects of people with serious heart disease...
  • New PAH Research Highlights Effect of Disease on Muscles, Importance of Exercise
  • (Pulmonary Hypertension News) Exercise and fitness are two health factors that invariably affect prognoses for most chronic, progressive diseases. Given the stress and immobility that come as a result of illness, maintaining fitness to the best of the patient’s ability is generally a best practice for maximizing quality of life and lifespan. However, new PAH research suggests that patients’ muscles are affected by the disease at the cellular level, and that any measure of exercise can have a palpably positive impact on health and well being.
  • Plant grown treatment for pulmonary hypertension
  • (Digital Journal) A new medication has been developed, which could retail at a far lower cost. The new product targets angiotensin II suppression hormones (angiotensins are peptide hormones that causes vasoconstriction and a subsequent increase in blood pressure.) The medication was formulated inside plant leaves. The material is then extracted, freeze-dried and then encased in capsules.

    In studies, Pharmaceutical International reports, the drug has been administered to rats. These studies found that the pulmonary hypertension levels in the rats dropped by around 20 percent. After two weeks of administration, the pressure levels inside the rats decreased by a further 12 percent. The rat based-trials not only produced pulmonary hypertension pressure drops of more than 30 percent, the drug further helped to improve heart function. The studies were conducted by the American Heart Association and the National Heart, Lung and Blood Institute.

News Archives
Take the Current Poll
View Current Poll Results To Date
View the Poll Archives